Introduction to bisphosphonates and the clinical pharmacology of alendronate

British Journal of Rheumatology

Volumn 36, Issue SUPPL. 1, 1997, Pages 10-14

  Russell, R G G ^a   Rogers, M J ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Alendronate; Bisphosphonates; Bone; Osteoporosis; Pharmacokinetics

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; PAMIDRONIC ACID; TILUDRONIC ACID;

BONE ATROPHY; BONE MASS; BONE METASTASIS; BONE TURNOVER; CLINICAL PHARMACOLOGY; DRUG ABSORPTION; DRUG ELIMINATION; DRUG MECHANISM; HUMAN; HYPERCALCEMIA; INTESTINE ABSORPTION; OSTEOLYSIS; OSTEOPOROSIS; PAGET BONE DISEASE; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0030818046     PISSN: 02637103     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (38)

1. Bijvoct O, HA Fleisch, RE Canfield, Russell RGG, eds. Bisphosphonates on bone. Amsterdam: Elsevier, 1995.
2. Fleisch H. Bisphosphonates in bone disease. New York: Parthenon, 1995.
3. Rogers MJ, Russell RGG. Mechanisms of action of bisphosphonates as inhibitors of bone resorption. In: Sharp P, ed. Paget's disease of bone. 1996:147-77.
4. Fleisch H, Russell RGG, Francis MD. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 1969;165:1262-4.
5. Schenk R, Merz WA, Muhlbauer R et al. Effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) and dichloromethylene diphosphonate (C12MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats. Calcif Tissue Res 1973;11:196-214.
6. Fleisch H, Bisaz S. Isolation from urine of pyrophosphate, a calcification inhibitor. Am J Physiol 1962;203:671-5.
7. Fleisch H, Neuman WF. Mechanisms of calcification: role of collagen, polyphosphates, and phosphatase. Am J Physiol 1961;200:1296-1300.
8. Fleisch H, Russell RGG, Straumann F. Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis. Nature 1966;212:901-3.
9. Fleisch HA, Russell RGG, Bisaz S et al. The inhibitory effect of phosphonates on the formation of calcium phosphate crystals in vitro and on aortic and kidney calcification in vivo. Eur J Clin Invest 1970;1:12-8.
10. Fleisch H, Russell RGG, Francis MD. Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science 1969; 165:1264-6.
11. Russell RGG, Muhlbauer RC, Bisaz S et al. The influence of pyrophosphate, condensed phosphates, phosphonates and other phosphate compounds on the dissolution of hydroxyapatite in vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathyroidectomised rats. Calcif Tissue Res 1970;6:183-96.
12. Shinoda H, Adamek G, Felix R et al. Structure-activity relationships of various bisphosphonates. Calcif Tiss Int 1983;35:87-99.
13. Geddes AD, D'Souza SM, Ebetino FH et al. Bisphosphonates: structure-activity relationships and therapeutic implications. Bone Miner Res 1994;8:265-306.
14. Schenk R, Eggli P, Fleisch H et al. Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat. Calcif Tissue Int 1986;38:342-9.
15. Sietsema WK, Ebetino FH, Salvagno AM et al. Antiresorptive dose-response relationships across three generations of bisphosphonates. Drugs Exp Clin Res 1989;15:389-96.
16. Muhlbauer RC, Bauss F, Schenk R et al. BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res 1991;6:1003-11.
17. Francis MD, Horancik K, Boyce RW. NE 58095 A diphosphonate which prevents bone erosion and preserves joint architecture in experimental arthritis. Int J Tissue React 1989;11:239-52.
18. Rogers MJ, Watts DJ, Russell RGG et al. Inhibitory effects of bisphosphonates on growth of amoebae of the cellular slime mould Dictyostelium discoideum. J Bone Miner Res 1994;9:1029-39.
19. Rogers MJ, Xiong X, Brown RJ et al. Structure-activity relationships of new heterocycle-containing bisphosphonates as inhibitors of bone resorption and as inhibitors of growth of Dictyostelium discoideum amoebae. Mol Pharmacol 1995;47:398-402.
20. Sato M, Grasser W, Endo N et al. Bisphosphonate action: alendronate localization in rat bone and effects of osteoclast ultrastructure. J Clin Invest 1991;88:2095-105.
21. Murakami H, Takahashi N, Sasaki T et al. A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders. Bone 1995;17:137-44.
22. Schmidt A, Rutledge SJ, Endo N et al. Protein tyrosine phosphatase activity regulates osteoclast formation and function. Inhibition by alendronate. Proc Natl Acad Sci 1996;93:3068-93.
23. Lowik C, van der Pluijm G. Mechanisms of action of bisphosphonates: studies with bone culture systems. In: Bijvoet O, Fleisch HA, Canfield RE, Russell RGG, eds. Bisphosphonates on bone. Amsterdam: Elsevier, 1995: 155-70.
24. Hughes DE, MacDonald BR, Russell RGG et al. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest 1989;83:1930-5.
25. Hughes DE, Wright KR, Uy HL et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995;10:1478-87.
26. Sahni M, Guenther HL, Fleisch H et al. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest 1993;91:2004-11.
27. Rogers MJ, Ji X, Russell RGG et al. Incorporation of bisphosphonates into adenine nucleotides by amoebae of the cellular slime mould Dictyostelium discoideum. Biochem J 1994;303:303-11.
28. Adami S, Bhalla AK, Dorizzi R et al. The acute-phase response after bisphosphonate administration. Calcif Tissue Int 1987;41:326-31.
29. Rodan GA, Seedor JG, Balena R. Preclinical pharmacology of alendronate. Osteoporos Int 1993;suppl 3:S7-12.
30. Toolan BC, Shea M, Myers ER et al. Effects of 4-amino-1-hyrdroxybutylidene bisphosphonate on bone biomechanics in rats. J Bone Miner Res 1992;7:1399-406.
31. Gertz Bj, Kline WF, Matuszewski BK et al. Oral bioavailability and dose proportionality of alendronate in postmenopausal women. J Bone Miner Res 1991;6(suppl 1):S279.
32. Lin JH, Chen I-W, Duggan DE. Effects of dose, sex, and age on the disposition of alendronate, a potent anti-osteolytic bisphosphonate, in rats. Drug Metab Dispos 1992;20:473-8.
33. Storm T, Thamsborg G, Steiniche T et al. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. New Engl J Med 1990;322:1265-71.
34. Watts NB, Harris ST, Genant HK et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990;323:73-9.
35. Smith R, Russell RGG, Bishop M. Diphosphonates and Paget's disease of bone. Lancet 1971;1:945-7.
36. Fleisch H. Bisphosphonates, pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease. Drugs 1991;42:919-42.
37. Adami S et al. Treatment of postmenopausal osteoporosis with continuous daily oral alendronate in comparison with either placebo or intranasal salmon calcitonin. Osteopor Int 1993;3:S217-S28.
38. Liberman UA, Weiss SR, Broll J et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995;333:1437-43.